26
|
Iezzi L, Mentuccia L, Vici P, Natoli C, Sperduti I, Astone A, Marchetti P, Pizzuti L, Michelotti A, Sini V, Cassano A, Ciancola F, Quadrini S, Moscetti L, Landucci E, Magnolfi E, Sergi D, Gamucci T. Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: a restrospective multicenter observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli M, Pastorino S, Pronzato P, Del Mastro L. Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv335.01] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Pizzuti L, Barba M, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Fancelli S, Grassadonia A, Michelotti A, Pescarmona E, Perracchio L, Maugeri-Saccà M, Vici P. Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Mentuccia L, Fabi A, Cassano A, Vici P, Michelotti A, Sperduti I, Sarobba G, Marchetti P, Scognamiglio M, Vaccaro A, Rossi E, Pellegrini D, Nicoletta D, Pellegrino A, Sini V, Pizzuti L, Palleschi M, Moscetti L, Jamara G, Ciancola F, Gamucci T. Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Scelzi E, Bernardi D, Bonciarelli G, Salesi N, Frassoldati A, Maisano R, Tagliaferri P, Gamucci T, Mencoboni M, Raggi T, Rosti G. Biosimilar epoetin alfa in the management of chemotherapy-induced aneamia: results from ANEMONE observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.29] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Fabbri M, Cortesi E, Marchetti P, Santini D, Gamucci T, Angelini F, Longo F, Milano A, Mancini M, Giuli A, Quadrini S, Sperduti I, Pellegrino A, Ratta R, Primi F, Chilelli M, Ruggeri E. 2544 Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31363-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Gamucci T, Mentuccia L, Vici P, Iezzi L, Sperduti I, Astone A, Marchetti P, Pizzuti L, Michelotti A, Sini V, Cassano A, Ciancola F, Quadrini S, Moscetti L, Landucci E, Sergi D, Magnolfi E, Natoli C. 1950 Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30898-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Pizzuti L, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Mentuccia L, Vaccaro A, Trenta P, Seminara P, Rapposelli I, Sini V, Santini D, Sperduti I, Marchetti P, Vici P. Her2-Positive Early Breast Cancer in the Pre-Trastuzumab and Trastuzumab Eras: a Triple Positive Subgroup Analysis of a Multicenter Retrospective Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Salvatore L, Cremolini C, Loupakis F, Masi G, Schirripa M, Marmorino F, Bergamo F, Zagonel V, Aprile G, Allegrini G, Tonini G, Zaniboni A, Amoroso D, Boni C, Gamucci T, Pinto C, Corsi D, D'Amico M, Bracarda S, Falcone A. Folfoxiri Plus Bevacizumab (Bv) or Plus Anti-Egfr Antibodies in Ras and Braf Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts): Analysis of Tumor Response. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Grande R, Pavese I, Natoli C, Ciancola F, Gemma D, Pellegrino A, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, Morano F, Sergi D, Signorelli C, Ruggeri E, Zampa G, Russano M, Gamucci T. Treatment (T) of Metastatic Colorectal Cancer (Mcrc) Patients (Pts) ≥75 Years (Y) Old in Clinical Practice: a Multicenter Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Mentuccia L, Vici P, Sperduti I, Pizzuti L, Moscetti L, Vaccaro A, Quadrini S, Magnolfi E, Fabbri M, Zampa G, Giampaolo M, Sergi D, Narducci F, Sacca MM, Gamucci T. Fact- B and Esas in Metastatic Breast Cancer (Mbc) Patients (Pts) Treated with Eribulin: Results of a Multicenter Prospective Observational Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu350.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, Passalacqua R, Iaffaioli V, Zilembo N, Mencoboni M, Roselli M, Pappagallo G, Pronzato P. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol 2013; 31:797. [PMID: 24307348 DOI: 10.1007/s12032-013-0797-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 11/27/2013] [Indexed: 12/13/2022]
Abstract
Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥ 20 % risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24-72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 10(9)/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 %), lung (18 %), and colorectal (13 %). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 % of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 % of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.
Collapse
|
38
|
Gamucci T, Moscetti L, Mentuccia L, Pizzuti L, Mauri M, Zampa G, Pavese I, Sperduti I, Vaccaro A, Vici P. Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. J Cancer Res Clin Oncol 2013; 140:221-6. [PMID: 24292401 PMCID: PMC3895217 DOI: 10.1007/s00432-013-1556-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Accepted: 11/18/2013] [Indexed: 01/05/2023]
Abstract
PURPOSE Diarrhea in relation to the lapatinib-capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥ 2 diarrhea incidence and, secondarily, treatment efficacy. PATIENTS AND METHODS Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m(2), starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. RESULTS Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1-2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. CONCLUSION The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of "conventional" administration of the lapatinib-capecitabine regimen.
Collapse
|
39
|
Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 2013; 139:853-60. [PMID: 23411686 PMCID: PMC3625404 DOI: 10.1007/s00432-013-1388-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Accepted: 01/29/2013] [Indexed: 01/03/2023]
Abstract
PURPOSE Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments remains controversial. In the present analysis, we evaluate recurrence risk in patients with pT1 a, b, c, node-negative, breast cancer, accordingly with some prognostic biological factors. METHODS We retrospectively evaluated 900 node-negative patients (pT1a, b, c) surgery treated between 2000 and 2009 in four Italian oncologic centers. We defined 3 different cohorts: ER positive (ER+); Her-2 positive (Her-2+); and triple negative (TN). RESULTS pT1a was seen in 7.6% of patients, 37.7 % pT1b, 54.8 % pT1c. Concerning the 3 different cohorts, 58.2 % were ER+; 10.8 % were Her-2+; 8.2 % were TN. Overall, chemotherapy was given to 3.0 %, 27.2 %, 69.8 % of pT1a, b, c, respectively, and to 22.7 %, 58.8 %, 68.9 % of ER+, Her-2+, TN subgroups. At a median follow-up of 67 months, 5-year DFS was 96.3 %, 89.2 %, 89.4 % in pT1a, b, c, respectively (100 %, 93.6 %, 89.8 % in ER+; 100 %, 78.7 %, 85.0 % in Her-2+; 100 %, 76.8 %, 85.2 % in TN) (p = ns). At multivariate analysis, histologic grade and Ki-67 resulted independent prognostic factors. Overall, 5-year OS was 98 %, without differences among pT1a, b, c, or among the 3 cohorts. CONCLUSIONS Overall, 5-year DFS was very favorable in this series of small, node-negative breast cancers, but Her-2+ and TN cohorts have a higher recurrence rate than ER+ cohort (p < 0.0001); pT1c, but also pT1b, in Her-2+ and TN subgroups, have a worse outcome, and effective chemotherapy treatment should be considered in these unfavorable subgroups.
Collapse
|
40
|
Silvestris N, Leo S, Di Palma T, De Vita F, Gamucci T, Barni S, Ferrara R, Mazzara C, Numico G, Colucci G. Natural History of Bone Metastasis in Gastric Cancer: Results of an Italian Multicenter Survey. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33260-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
41
|
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva R, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 2012; 23:1436-41. [DOI: 10.1093/annonc/mdr474] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
42
|
Vaccaro A, Ciancola F, Vici P, Sperduti I, Moscetti L, Pizzuti L, Di Seri M, Ruggeri E, Giampaolo M, Gamucci T. 5187 POSTER Unfavourable Prognosis in PT1b HER2 Positive and Triple Negative Breast Cancer Patients. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71629-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Moscetti L, Cortesi E, Gamucci T, Sperduti I, Pavese I, Franco D, Alesini D, Fabbri A, Grande R, Gemma D, Signorelli C, Ruggeri E. Maintenance treatment with bevacizumab after chemotherapy (CT) plus B in metastatic colorectal cancer: An Italian multicenter retrospective analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Grande R, Narducci F, Mansueto G, Gemma D, Sperduti I, Bianchetti S, Angelini F, Trombetta G, Gamucci T. Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and limecicline—A phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Vici P, Longo F, Ruggeri E, Di Seri M, Giampaolo MA, Gamucci T. High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative early breast cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Mangili G, Sigismondi C, Lorusso D, Cormio G, Scollo P, Viganò R, Gamucci T, Candiani M, Pignata S. Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol 2011; 121:280-4. [PMID: 21277010 DOI: 10.1016/j.ygyno.2011.01.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Revised: 12/26/2010] [Accepted: 01/03/2011] [Indexed: 11/28/2022]
Abstract
OBJECTIVE Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for pure ovarian dysgerminoma (POD), except for correctly staged IA patients. The aim of study was to evaluate the outcome of IA POD patients with incomplete surgical staging in order to define the proper management. METHODS Data concerning primary treatment and recurrence were reviewed for 26 patients with stage IA POD treated in MITO (Multicenter Italian Trials in Ovarian Cancer) centers. RESULTS Median age was 22.5years. Primary surgery was fertility sparing for 17 patients (65.4%) and radical surgery was performed in 9 patients due to older age or gonadal dysgenesis. Only five patients (19.2%) had complete surgical staging; 38.5% had lymph node dissection, 46.2% had peritoneal biopsies and/or omentectomy and 65.4% had peritoneal washing. Seven patients received adjuvant chemotherapy. Overall recurrence rate was 11.5%: all recurrences occurred in the group submitted to incomplete staging procedure. No patients treated with adjuvant chemotherapy relapsed. One patient had pelvic recurrence, one patient relapsed in the abdomino-pelvic peritoneum and lymph nodes and the third patient showed a peritoneum, lymph nodal and residual ovary relapse. All patients with recurrence were cured by salvage therapy: 2 patients were treated with surgery plus chemotherapy and one only with chemotherapy. After a median follow-up of 100months all patients are alive without evidence of disease. Six patients opted for conception and delivered healthy infants, two with IVF with donor oocyte. CONCLUSIONS IA POD prognosis is excellent. Conservative surgery with a complete surgical staging is the gold standard. Patients with incomplete staging could undergo surgical restaging or surveillance. Chemotherapy should be reserved to relapse with excellent chances of therapeutic success.
Collapse
|
48
|
Musolino A, Bisagni G, De Matteis A, Nuzzo F, Ardizzoni A, Crinò L, Gamucci T, Passalacqua R, Gnoni R, Boni C. Abstract P2-17-01: Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-17-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel (T; Taxotere) with capecitabine (X) is active against metastatic breast cancer (MBC); bevacizumab (B) has demonstrated efficacy with taxanes in the first-line setting. This study was conducted to assess the efficacy and safety of TX-B in patients (pts) with MBC. Patients and methods: In this single-arm, multicenter phase II study, pts received first-line bevacizumab 15 mg/kg and docetaxel 60 mg/m2 on day 1, plus capecitabine 900 mg/m2 twice per day on days 1-14 every 21 days. The treatment was administrated for 3 cycles and in case of objective response or stable disease at that time, pts were treated with 3 additional cycles. More courses of chemotherapy were administered at Investigator's discretion. Bevacizumab was continued until progressive disease, patient refusal, or unacceptable toxicity. Primary end point was progression-free survival (PFS) and secondary end points were tumor response rate (RR), overall survival (OS), and toxicity.
Results: We report data from the first 30 pts enrolled. Median age was 54 (37-72). Eight (27%) pts had triple-negative disease, while 18 (60%) were hormone-receptor positive. HER2 status was recognized as negative in 25 (84%) pts. TX-B was administered for a median of seven cycles. Five complete and 13 partial responses were observed (overall RR 60%). Median response duration was 12 months. Median OS and PFS were 26 and 11 months, respectively. Grade 3/4 adverse events included tromboembolism (10%), neutropenia (23%), hand-foot syndrome (13%), stomatitis (10%). The median TX doses administered per cycle were 60 mg/m2 and 660 mg/m2, respectively. Ten (33%) pts required dose reductions of docetaxel, while capecitabine dose was reduced in 15 (50%) pts. Results of all the 80 assessable pts entered in the study will be presented at the meeting.
Conclusion: TX-B demonstrated significant activity with an acceptable toxicity profile. Maintenance therapy with B is possible for a long period of stable tumor disease.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-17-01.
Collapse
|
49
|
Grande R, Cianci G, Sperduti I, Gemma D, Gelibter A, Giampaolo M, Mentuccia L, Narducci F, Magnolfi E, Gamucci T. FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Milella M, Vaccaro V, Sperduti I, Bria E, Gelibter A, Mansueto G, Moscetti L, Gamucci T, Ruggeri E, Cognetti F. Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14565] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|